This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: NexMed

Dan M. asks, " What's the story with Targacept(TRGT)?"

I love Targacept for its experimental depression drug TC-5214. The phase II data on TC-5214 that Targacept presented last October was phenomenal, and it led to the signing of a monster partnership with AstraZeneca in December.

TC-5214 is going to be a huge drug in the depression treatment market. The problem for a lot of investors looking at Targacept today is time -- there's too much of it between now and when AstraZeneca and Targacept plan to start the first phase III study of TC-5214 in the middle of the year.

My sense is that Targacept is viewed as being catalyst deprived, which is the kiss of death for a lot of investors who figure, 'why own a stock now if there's no trade-able event on the near horizon?'

I can understand that sentiment, but I also know that Targacept at $20 a share and an enterprise value of $500 million is a total steal based on the blockbuster potential of TC-5214. Patience will be rewarded.
3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $0.32 6.70%
OPTR $0.00 0.00%
IMGN $7.09 1.00%
KERX $3.24 0.31%
TRGT $2.01 -6.94%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs